Christopher Yea

Christopher Yea, listed as senior executive, appears in our data through filings on KalVista Pharmaceuticals, Inc. shares, published by SEC (Form 4). Over a trading history stretching from 21 November 2016 to 23 February 2026, the count stands at 89 filings.

Sales make up the whole of the open-market record (50 sales, €3.5M). Besides market trades, the filings include 3 share grants and 36 option exercises. Since January 2026: no purchases and 2 sales on the market.

On 24 February 2026 came the latest disclosure, an option exercise in KalVista Pharmaceuticals, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. The legal deadline for a Form 4 is two business days after the transaction. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.